Table 3.
Clinical characteristics of patients and distributions of sPD-L1 concentrations according to the therapeutic response to EGFR-TKIs.
| Objective response rate (ORR) | P | ||
|---|---|---|---|
|
Yes N = 35 |
No N = 31 |
||
| Gender | |||
| Female | 46.7 (14/30) | 53.3 (16/30) | 0.344 |
| Male | 58.3 (21/36) | 41.7 (15/36) | |
| Age | |||
| <61 | 63.6 (21/33) | 36.4 (12/33) | 0.084 |
| ≥61 | 42.4 (14/33) | 57.6 (19/33) | |
| ECOG PS | |||
| 0–1 | 54.7 (35/64) | 45.3 (29/64) | 0.217 |
| 2 | 0.0 (0/2) | 100.0 (2/2) | |
| Stage | |||
| Recurrence | 40.0 (4/10) | 60.0 (6/10) | 0.581 |
| IIIb/IV | 55.4 (31/56) | 44.6 (25/56) | |
| Smoking | |||
| Never | 50.0 (25/50) | 50.0 (25/50) | 0.383 |
| Current/former | 62.5 (10/16) | 37.5 (6/16) | |
| EGFR Status | |||
| 19DEL | 57.6 (19/33) | 42.4 (14/33) | 0.459 |
| L858R and others | 48.5 (16/33) | 51.5 (17/33) | |
| TKIs | |||
| Gefitinib | 53.1 (26/49) | 46.9 (23/49) | 0.734 |
| Erlotinib | 50.0 (1/2) | 50.0 (1/2) | |
| Icotinib | 46.2 (6/13) | 53.8 (7/13) | |
| Afatinib | 100.0 (2/2) | 0.0 (0/2) | |
| Brain Metastasis | |||
| Yes | 63.6 (14/22) | 36.4 (8/22) | 0.222 |
| No | 47.7 (21/44) | 52.3 (23/44) | |
| Plasma sPD-L1 Levels (Pre-treatment) | |||
| <568.19 | 66.7 (22/33) | 33.3 (11/33) | 0.026 |
| ≥568.19 | 39.4 (13/33) | 60.6 (20/33) | |
| Plasma sPD-L1 Levels (On-treatment) | |||
| <560.99 | 73.9 (17/23) | 26.1 (6/23) | 0.025 |
| ≥560.99 | 43.5 (10/23) | 56.5 (13/23) | |
| Plasma sPD-L1 Reduction | |||
| Yes | 60.9 (14/23) | 39.1 (9/23) | 0.765 |
| No | 56.5 (13/23) | 43.5 (10/23) | |
| T790M Detected at Progression | |||
| Yes | 68.2 (15/22) | 31.8 (7/22) | 0.132 |
| No | 43.8 (7/16) | 56.2 (9/16) | |
NSCLC-NOS, non-small cell lung cancer-not otherwise specified; ECOG PS, Eastern Cooperative Oncology Group performance status.
L858R and others, one patient had a L858R and L861Q co-mutation.
P-values are calculated using Chi-square test or Fisher's exact test. Bolded p-values indicate significance.